Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia research 2023-07, Vol.130, p.107313-107313, Article 107313
Hauptverfasser:	Oya, Shuki, Ozawa, Hidetoshi, Maehiro, Yoshimi, Nakamura, Takayuki, Takaki, Yusuke, Fukuyama, Toshinobu, Yamasaki, Yoshitaka, Yamaguchi, Maki, Aoyama, Kazutoshi, Mouri, Fumihiko, Nagafuji, Koji
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia Azacitidine - therapeutic use Azacytidine Bridged Bicyclo Compounds, Heterocyclic - therapeutic use FLT3 inhibitor fms-Like Tyrosine Kinase 3 - genetics Humans Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Measurable residual disease Mutation Nuclear Proteins - genetics Nucleophosmin Prognosis Venetoclax
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!